The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Simaniv T.O.

Research Center of Neurology

Kochergin I.A.

Research Center of Neurology

Zakharova M.N.

Research Center of Neurology

Korobko D.S.

State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University

Zaslavsky L.G.

Pavlov First Saint Petersburg State Medical University

Zelenova O.V.

Federal Research Institute for Health Organization and Informatics

Abramov S.I.

Federal Research Institute for Health Organization and Informatics

Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population

Authors:

Simaniv T.O., Kochergin I.A., Zakharova M.N., Korobko D.S., Zaslavsky L.G., Zelenova O.V., Abramov S.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7): 96‑103

DOI: 10.17116/jnevro202112107196

Read: 2517 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF NEUROMYELITIS OPTIC SPECTRUM DISEASES IN THE RUSSIAN POPULATION
CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF NEUROMYELITIS OPTIC SPECTRUM DISEASES IN THE RUSSIAN POPULATION

To cite this article:

Simaniv TO, Kochergin IA, Zakharova MN, Korobko DS, Zaslavsky LG, Zelenova OV, Abramov SI. Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7):96‑103. (In Russ.)
https://doi.org/10.17116/jnevro202112107196

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Prevalence of postpartum depression in the Russian Fede­ration: a systematic review and meta-analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):74-87
Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medi­cine. 2025;(7):111-118
Non-alcoholic fatty liver disease: a view formation on the problem and its significance for the clinical practice. Russian Journal of Preventive Medi­cine. 2025;(7):127-132
Abstract:

OBJECTIVE

To present clinical and epidemiological aspects of neuromyelitis optica spectrum disorders (NMOSD) in the Russian Federation.

MATERIAL AND METHODS

We studied 142 patients who met diagnostic criteria of 2015 for NMOSD. Sex, age at disease onset, presence or absence of aquaporin-4 immunoglobulin G antibodies (AQP4-IgG), mail clinical symptoms, oligoclonal IgG, therapy for the treatment of exacerbations and prevention of exacerbations, compliance with 2006 diagnostic criteria were assessed.

RESULTS

The prevalence of women is 4.26:1, the most frequent age at disease onset is 18—29 years (36% of cases). The laboratory aspects of the disease are characterized and approaches to the treatment and prevention of exacerbations of NMOSD in patients of the Russian population are evaluated. Approaches to diagnostics are compared depending on the applied diagnostic criteria (34% of patients do not meet neuromyelitis optica 2006 diagnostic criteria). A prognosis for the prevalence of NMOSD in the Russian population has been proposed: 0.45—4.21/100000.

CONCLUSION

This is the first published data on clinical and epidemiological characteristics of NMOSD in the Russian Federation.

Keywords:

neuromyelitis optica (NMO)
neuromyelitis optica spectrum disorders (NMOSD)
multiple sclerosis
myelin oligodendrocyte glycoprotein immunoglobulin G antibodies (MOG-IgG)
aquaporin-4 immunoglobulin G antibodies (AQP4-IgG)
demyelinating diseases
epidemiology

Authors:

Simaniv T.O.

Research Center of Neurology

Kochergin I.A.

Research Center of Neurology

Zakharova M.N.

Research Center of Neurology

Korobko D.S.

State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University

Zaslavsky L.G.

Pavlov First Saint Petersburg State Medical University

Zelenova O.V.

Federal Research Institute for Health Organization and Informatics

Abramov S.I.

Federal Research Institute for Health Organization and Informatics

Received:

08.04.2021

Accepted:

24.05.2021

Close metadata

References:

  1. Simaniv TO, Vasil’ev AV, Askarova LSh, Zakharova MN. Neuromyelitis optica and neuromyelitis optica spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry (Special Issues). 2019;119(10-2):35-48. (In Russ.). https://doi.org/10.17116/jnevro20191191035
  2. Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Current Opinion in Neurology. 2019;32(3):385-394.  https://doi.org/10.1097/WCO.0000000000000694
  3. Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169-176.  https://doi.org/10.7861/clinmedicine.19-2-169
  4. Bakulin IS, Simaniv TO, Konovalov RN, Zakharova MN. Area postrema lesion as a cause of intractable nausea, vomiting and hiccups in neuromyelitis optica spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry (Special Issues). 2017;117(10-2):20-23. (In Russ.). https://doi.org/10.17116/jnevro201711710220-23
  5. Juryńczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, Waters P, Kuker W, Craner M, Weir A, DeLuca GC, Kremer S, Leite MI, Vincent A, Jacob A, de Sèze J, Palace J. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88(2):132-136.  https://doi.org/10.1136/jnnp-2016-314005
  6. de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P. Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler. 2003;9(5):521-525.  https://doi.org/10.1191/1352458503ms947oa
  7. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-2112. https://doi.org/10.1016/S0140-6736(04)17551-X
  8. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477.  https://doi.org/10.1084/jem.20050304
  9. Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Archives of Neurology. 2010;67(8):1016-1017. https://doi.org/10.1001/archneurol.2010.188
  10. Kira JI. Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? Mult Scler. 2017;23(9):1300-1302. https://doi.org/10.1177/1352458517703803
  11. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489. https://doi.org/10.1212/01.wnl.0000216139.44259.74
  12. Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014;20(7):843-847.  https://doi.org/10.1177/1352458513507822
  13. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.  https://doi.org/10.1212/WNL.0000000000001729
  14. Wang X, Chen X, Zhu C, Ma H, Wang F, Qin L, Li W. A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG. Medicine (Baltimore). 2018;97(48):e13100. https://doi.org/10.1097/md.0000000000013100
  15. Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412.  https://doi.org/10.1016/s1474-4422(20)30078-8
  16. Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363. https://doi.org/10.1016/s0140-6736(19)31817-3
  17. Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S; PREVENT Study Group. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord. 2021;47:102641. https://doi.org/10.1016/j.msard.2020.102641
  18. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, Paul F, Levy M. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66-72.  https://doi.org/10.1016/j.msard.2018.07.025
  19. Eliseeva DD, Vasiliev AV, Shabalina AA, Simaniv TO, Zakharova MN. Myelin oligodendrocyte glycoprotein immunoglobulin G-associated encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry (Special Issues). 2020;120(7-2):13-23. (In Russ.). https://doi.org/10.17116/jnevro202012007213
  20. Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad SE, Sahraian MA, Azimi AR, Harirchian MH, Asgari N, Naser Moghadasi A. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2019;27:350-363.  https://doi.org/10.1016/j.msard.2018.11.008
  21. Prasad S, Chen J. What You Need to Know About AQP4, MOG, and NMOSD. Semin Neurol. 2019;39(6):718-731.  https://doi.org/10.1055/s-0039-3399505
  22. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775-783.  https://doi.org/10.1002/ana.24617
  23. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite M, Kleiter I, Chitnis T, Consortium GIC, Optica BfN. Demographic and clinical features of neuromyelitis optica: a review. Multiple Sclerosis Journal. 2015;21(7):845-853.  https://doi.org/10.1177/1352458515572406
  24. Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, Jacob A, Kira JI, Leite MI, Marignier R, Miyamoto K, Palace J, Saiz A, Sepulveda M, Sveinsson O, Illes Z. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2021;96(2):59-77.  https://doi.org/10.1212/wnl.0000000000011153
  25. Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult Scler Int. 2015;2015:174720. https://doi.org/10.1155/2015/174720
  26. Asgari N, Lillevang S, Skejoe H, Falah M, Stenager E, Kyvik K. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76(18):1589-1595. https://doi.org/10.1212/wnl.0b013e3182190f74
  27. Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, Pickersgill T, te Water Naudé J, Robertson N. The prevalence of neuromyelitis optica in South East Wales. European Journal of Neurology. 2012;19(4):655-659.  https://doi.org/10.1111/j.1468-1331.2011.03529.x
  28. Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan SV, Nasr Z. An epidemiological study of neuromyelitis optica in Isfahan. Multiple Sclerosis Journal. 2014;20(14):1920-1922. https://doi.org/10.1177/1352458514537699
  29. Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, Das K, Boggild M. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. Journal of Neurology. 2013;260(8):2134-2137. https://doi.org/10.1007/s00415-013-6926-y
  30. Cabre P, Gonzalez-Quevedo A, Lannuzel A, Bonnan M, Merle H, Olindo S, Chausson N, Lara-Rodriguez R, Smadja D, Cabrera-Gomez J. Descriptive epidemiology of neuromyelitis optica in the Caribbean basin. Revue Neurologique. 2009;165(8-9):676-683.  https://doi.org/10.1016/j.neurol.2009.02.012
  31. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. Journal of Neurology. 2009;256(1):35-44.  https://doi.org/10.1007/s00415-009-0009-0
  32. Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Multiple Sclerosis Journal. 2014;20(12):1651-1653. https://doi.org/10.1177/1352458514521503
  33. Houzen H, Niino M, Hirotani M, Fukazawa T, Kikuchi S, Tanaka K, Sasaki H. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. Journal of the Neurological Sciences. 2012;323(1-2):117-122.  https://doi.org/10.1016/j.jns.2012.08.032
  34. Rivera JF, Kurtzke JF, Booth VA, Corona T. Characteristics of Devic’s disease (neuromyelitis optica) in Mexico. Journal of Neurology. 2008;255(5):710-715.  https://doi.org/10.1007/s00415-008-0781-2
  35. Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler. 2018;24(14):1843-1851. https://doi.org/10.1177/1352458517735191
  36. Jonsson DI, Sveinsson O, Hakim R, Brundin L. Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study. Neurology. 2019;93(2):181-189.  https://doi.org/10.1212/wnl.0000000000007746
  37. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020;11:501.  https://doi.org/10.3389/fneur.2020.00501
  38. Miyamoto K, Fujihara K, Kira J-i, Kuriyama N, Matsui M, Tamakoshi A, Kusunoki S. Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry. 2018;89(6):667-668.  https://doi.org/10.1136/jnnp-2017-317321
  39. Bukhari W, Prain KM, Waters P, Woodhall M, O’Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017;88(8):632-638.  https://doi.org/10.1136/jnnp-2016-314839
  40. Papp V, Illes Z, Magyari M, Koch-Henriksen N, Kant M, Pfleger CC, Roemer SF, Jensen MB, Petersen AE, Nielsen HH, Rosendahl L, Mezei Z, Christensen T, Svendsen K, Hyldgaard Jensen PE, Lydolph MC, Heegaard N, Frederiksen JL, Sellebjerg F, Stenager E, Petersen T. Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology. 2018;91(24):2265-2275. https://doi.org/10.1212/wnl.0000000000006645
  41. Papp V, Iljicsov A, Rajda C, Magyari M, Koch-Henriksen N, Petersen T, Jakab G, Deme I, Nagy F, Imre P, Lohner Z, Kovács K, Birkás AJ, Köves Á, Rum G, Nagy Z, Kerényi L, Vécsei L, Bencsik K, Jobbágy Z, Diószeghy P, Horváth L, Galántai G, Kasza J, Molnár G, Simó M, Sátori M, Rózsa C, Ács P, Berki T, Lovas G, Komoly S, Illes Z. A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary. Eur J Neurol. 2020;27(2):308-317.  https://doi.org/10.1111/ene.14079
  42. Kim S-H, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung H-P, Asgari N. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):2089-2099. https://doi.org/10.1212/wnl.0000000000006574
  43. Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(6):555-556.  https://doi.org/10.1136/jnnp-2017-317566
  44. Starodubov VI, Zelenova OV, Abramov SI, Sterlikov SA, Oskov YuI, Belyakova NV. The first observational epidemiological study to determine the incidence and prevalence of diseases range of neuromyelitis optica (Devik`s disease) on the territory of the Russian Federation. Current Problems of Health Care and Medical Statistics. 2021;1:130-141. (In Russ.). https://doi.org/10.24411/2312-2935-2021-00007
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.